LogoPressRelease.jpg
ImmunoGenomics and Vero Diagnostics Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
16 sept. 2020 08h30 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm Announces Agenda for 9th Annual Mass Cytometry Summit
15 sept. 2020 08h30 HE | Fluidigm Corporation
Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry Leading Academic and Pharma Researchers Detail Latest CyTOF Based...
LogoPressRelease.jpg
Fluidigm Achieves Initial Milestone under NIH Rapid Acceleration of Diagnostics Agreement
08 sept. 2020 08h30 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm to Participate at the 2020 Cantor Virtual Global Healthcare Conference
02 sept. 2020 16h02 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR  Assay for COVID-19
25 août 2020 23h00 HE | Fluidigm Corporation
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System  Demonstrated 100 Percent...
LogoPressRelease.jpg
Fluidigm Announces Second Quarter 2020 Financial Results
06 août 2020 16h05 HE | Fluidigm Corporation
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
LogoPressRelease.jpg
Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis
04 août 2020 08h30 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative
31 juil. 2020 11h10 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
GnomeDX Files for FDA Emergency Use Authorization for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing the Fluidigm Biomark HD Platform
20 juil. 2020 08h30 HE | Fluidigm Corporation
Test Intended to Expand Availability of COVID-19 Screening Resources in Central Ohio Workflow with Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Increasing Number of Labs...
LogoPressRelease.jpg
Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
06 juil. 2020 16h02 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...